Introducing The New Purdue Pharma

Mark Timney has been president and CEO of US specialty company Purdue Pharma for just over two years but he's playing a long game to pull the business away from its single-track R&D model towards other opportunities outside pain therapy – its mainstay development area

Mark Timney has been president and CEO of US specialty company Purdue Pharma for just over two years but he's playing a long game to pull the business away from its single-track R&D model towards other opportunities outside pain therapy – its mainstay development area

Timney, who was previously president of Merck US but joined Purdue in January 2014, spoke with Scrip's Lucie Ellis during...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category